NCT07226947Recruiting
Body Composition and Exercise to Prevent Muscle Loss With GLP1 Agonist Treatment
BIA Monitoring and Exercise for the Prevention of Muscle Loss With Incretin Therapy (BICEP Study)
Source: ClinicalTrials.gov · Last updated 30 Dec 2025
Brief summary (registry, in English)
The goal of this study is to learn if a smartwatch that measures activity level and body composition, combined with exercise reminders, can safely improve strength and muscle mass in people who recently started or are planning to start treatment with incretin therapy (liraglutide, semaglutide, tirzepatide or retatrutide), also known as glucagon-like peptide 1 receptor agonist (GLP-1 RA) medications.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- First submitted
- 6 Nov 2025
- Start date
- 24 Nov 2025
- Primary completion date
- Jun 2027
- Lead sponsor
- Massachusetts General Hospital
- Diseases
- Obesity
- NCT number
- NCT07226947
What you commit to
- Study type: Interventional
- Planned participants: 100
- From 24 Nov 2025 to the primary completion date, Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Current pregnancy (positive urine hCG) or plans to become pregnant in the next 6 months
- BMI \<25 kg/m2 at the time of screening
- Unable to participate in a regular physical exercise program
- Implanted pacemaker
- Any factors that, in the opinion of the principal investigator, would interfere with the safe completion of the study
Who the study is looking for
- Age ≥ 18 years old at time of signing informed consent
- Started treatment with incretin therapy (liraglutide, semaglutide, tirzepatide, or retatrutide) within the past 2 months or planning to start this treatment
- Potential participants switching GLP1-RA therapies due to inadequate response to a prior treatment will be eligible for enrollment
- Able to provide informed consent
Age in the registry: 18 years to 99 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Diabetes Research Center Coordinator of this site? Confirm its status | Boston | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.